drugset / Trial / NCT05618613
Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.
Timeline
- Start
- 2022-12-02
- Primary completion
- 2023-06-23
- Completion
- 2023-06-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elacestrant | Other / unclassified | 200 mg | Oral |
| Subject | Elacestrant | Other / unclassified | 300 mg | Oral |
| Subject | Elacestrant | Other / unclassified | 400 mg | Oral |
| Subject | Onapristone | Other / unclassified | 40 mg | Oral |
| Subject | Onapristone | Other / unclassified | 50 mg | Oral |